抗动脉粥样硬化战略先行.pptVIP

可定20mg能降LDL-C达50%以上 STELLAR研究是一项大规模、多中心、平行分组、开放试验，比较了辛伐他汀、普伐他汀、阿托伐他汀和瑞舒伐他汀各个剂量范围的疗效，共入选高胆固醇血症的患者2431例，分别使用瑞舒伐他汀10、20或40 mg/d，阿托伐他汀10、20、40或80 mg/d，辛伐他汀10、20、40或80 mg/d，普伐他汀10、20或40 mg/d治疗。研究结果表明，6周后瑞舒伐他汀总体降LDL-C的疗效明显优于其他他汀，10mg的瑞舒伐他汀能使患者LDL-C下降46%，优于阿托伐他汀20mg，而20mg的降脂幅度则与阿托伐他汀80mg相似。 * A previous study (Khot et al 2003) examined the prevalence of the four conventional cardiovascular risk factors (smoking, hypertension, hypercholesterolaemia and diabetes mellitus) in 87 869 male patients with CHD, excluding CHD as a risk factor. The majority of patients had ≤1 risk factor, suggesting that other factors, such as inflammation, may play an important role in CHD. Reference Khot UN et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898–904. Abbreviation CHD=coronary heart disease * 冠状动脉粥样硬化是一种慢性持续进展的病变，既往的大规模他汀类药物的降脂研究（如REVERSAL研究等）证实：他汀类药物治疗可预防动脉粥样硬化的进展，稳定动脉粥样硬化病变。 ASTEROID研究是首个用确凿证据来证明强化他汀类药物治疗能逆转冠状动脉粥样硬化脂质斑块沉积的大规模临床研究，具有里程碑式的意义。 * A previous study (Khot et al 2003) examined the prevalence of the four conventional cardiovascular risk factors (smoking, hypertension, hypercholesterolaemia and diabetes mellitus) in 87 869 male patients with CHD, excluding CHD as a risk factor. The majority of patients had ≤1 risk factor, suggesting that other factors, such as inflammation, may play an important role in CHD. Reference Khot UN et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898–904. Abbreviation CHD=coronary heart disease * * 研究显示：瑞舒伐他汀常规剂量2.5-20mg全面调脂，有效降低LDL-C 38.6%，升高HDL-C19.8%。 * A previous study (Khot et al 2003) examined the prevalence of the four conventional cardiovascular risk factors (smoking, hypertension, hypercholesterolaemia and diabetes mellitus) in 87 869 male patients with CHD, excluding CHD as a risk factor. The majority of patients had ≤1 risk factor, suggesting that other factors, such as inflammation, may play an important role in CHD.